For 16 years, Canvax has been an Original Manufacturer & Supplier of the Most Innovative Solutions, Services, Kits and R&D Reagents inside the Molecular & Cell Biology field. Thanks to our reliable, cost-effective and easy-to-use products, we enable our worldwide Customers to improve its Laboratory Productivity and Accelerate their Discoveries.
Based in Córdoba (Spain), since its foundation Canvax has focused on R&D of Multiplex High Throughput Platforms (HTS) for Drug discovery and Diagnostic applied Biosensors. Over a decade later, Canvax is a worldwide leading Expert in Molecular Biology and GPCR Expression in Heterologous Cells, with important Patents and exclusive Know-how. Canvax prides itself to be the First company to obtain an Unprecedented Milestone that will revolutionize the Diagnostics sector:
Canvax established stable high-level expression of odour GPCRs into heterologous cell lines in 2014.
With several awards as relevant Innovative Company, Canvax markets all its unmatched know-how, exclusive expertise and worldwide leading R&D knowledge through its original manufactured innovative solutions, kits and R&D Reagents within the Molecular Biology.
Thanks to our sustained commitment to R&D, exclusive Patents and unmatched Know-how, Canvax has prominent outcomes within the following business areas: Drug Discovery, Nutraceuticals, R&D Reagents, Biosensors and Molecular Nose.
Canvax has built a unique ecosystem of Excellency for drug discovery and development, to cover unmet clinical needs in disorders such as cancer and central nervous system diseases. It is supported by a worldwide expert network in disease target validation, screening of novel molecular libraries against both kinases and GPCRs, medicinal chemistry, in vitro and in vivo studies, ADME and toxicology studies.
One patented lead molecule, Bozinib, is already in Preclinical Research and has shown promising properties as Anticancer Agent, specifically against Cancer Stem Cells, the resistant core of cancers. Three more programs are ready to enter the Drug Discovery phase using Canvax´s exclusive screening Patented platform, FRIDAGPCR, a robust cell-based homogeneous assay validated for Cancer and Central Nervous System GPCRs.
FRIDAGPCR Screening technology allows us to outline a diversified pipeline of Innovative Drugs.
Oxidative stress is a common hallmark of several neurological diseases like Alzheimer, Parkinson, Schizophrenia, Multiple Sclerosis and Huntington diseases, and the imbalance in the oxidation-reduction equilibrium is also related to the pathogenesis of Cardiovascular Disease and Metabolic Syndrome.
Canvax, in collaboration with IMIBIC (Córdoba, Spain), have developed a patented formulation from a vegetal source that ameliorates significantly oxidative stress in an animal model of Multiple Sclerosis. In addition, Canvax´s Scientists have developed a process that improves 14-fold the yield of the active molecule, when compared to the best industrial process used today, and such process